Additionally, the current study indicates that during hyperoxia treatment in premature infants, any approach or drug that can activate Nrf2 and inhibit the NLRP3 inflammasome may serve as an effective therapeutic strategy for BPD. This evidence concerns the gene NLRP3 and bronchopulmonary dysplasia.